Stevanato Group Q4 2025 Earnings Call Insights

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 1 hour ago

0mins

STVN+18.81%

Should l Buy STVN?

Source: seekingalpha

Significant Revenue Growth: Stevanato Group reported a 9% increase in total revenue for fiscal 2025 at constant currency, with a 7% rise on a reported basis, highlighting strong demand in the Biopharmaceutical and Diagnostic Solutions (BDS) segment which achieved double-digit growth.
High-Value Product Performance: Revenue from high-value solutions surged 31% to EUR 171 million, accounting for approximately 49% of total revenue, indicating the company's strengthening competitive position in the high-value syringe market, particularly driven by demand for the Nexa syringe.
Optimistic Future Outlook: The company projects 2026 revenue between EUR 1.260 billion and EUR 1.290 billion, with the BDS segment expected to grow in the high-single to low-double digits, reflecting confidence in ongoing investments and market demand for high-value products.
Engineering Segment Challenges: Despite strong performance in high-value solutions, the Engineering segment saw a 23% revenue decline, indicating challenges with longer order intake cycles, prompting management to adopt a cautious stance while emphasizing the need to balance capacity expansion with market demand.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy STVN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on STVN

Wall Street analysts forecast STVN stock price to rise

3 Analyst Rating

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 14.730

Low

24.00

Averages

27.00

High

30.00

Current: 14.730

Low

24.00

Averages

27.00

High

30.00

Jefferies

Hold

downgrade

$23

2026-02-10

Reason

Jefferies

Price Target

$23

AI Analysis

2026-02-10

downgrade

Hold

Reason

Jefferies lowered the firm's price target on Stevanato Group to $17.50 from $23 and keeps a Hold rating on the shares. Injectable packaging Contract Manufacturing Organizations face headwinds from vaccines and shifts to oral and multi-dose GLP-1 formats, though the firm thinks oral GLP-1 risk is "largely priced in," the analyst tells investors.

KeyBanc

maintain

$200 basis points

2025-12-24

Reason

KeyBanc

Price Target

$200 basis points

2025-12-24

maintain

Reason

KeyBanc believes the risk to oral weight loss drugs remains limited to 2030 from the approval of Wegovy's oral version. Oral GLP-1 market penetration will remain capped in the near and long term despite new market approvals, the analyst tells investors in a research note. KeyBanc believes the oral version of Wegovy will only contribute 200 basis points to overall GLP-1 market share by 2030. The firm thinks GLP-1 suppliers are likely conservative with their market assumptions. West Pharmaceutical (WST) and Stevanato Group (STVN) have both commented on their market assumption that orals will have 30% market share of the overall GLP-1 market, it notes. KeyBanc expects both suppliers to continue to ramp as the market launches next-generation GLP-1s in injectable format.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for STVN

Unlock Now

About STVN

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Stevanato Group Establishes Fiscal 2026 Guidance

19 hours agoNewsfilter

2025 Fiscal Year Growth: Stevanato Group reported a 7% year-over-year revenue increase to €1.186 billion for fiscal 2025, with gross profit margin rising by 160 basis points to 29.0%, indicating strong performance in the biopharmaceutical sector that is expected to enhance future profitability and market share.
Strong Q4 Performance: In Q4 2025, revenue grew by 5% to €346.5 million, with high-value solutions accounting for 49% of total revenue, reflecting the company's strengthened competitiveness in the premium market, which is likely to attract more customers and orders.
Optimistic 2026 Guidance: The company expects revenue for fiscal 2026 to range between €1.26 billion and €1.29 billion, with adjusted EBITDA projected between €331.8 million and €346.9 million, showcasing management's confidence in future growth, particularly in the expanding biopharmaceutical market.
Cash Flow and Capital Expenditures: As of December 31, 2025, the company had cash and cash equivalents of €130.6 million and net debt of €337.7 million, indicating a solid liquidity position while supporting future strategic investments and operational needs.